



**7<sup>th</sup> Theranostics World Congress**  
March 22–24, 2024  
Santiago, Chile



**PROGRAM  
GUIDE**



# WE LOOK FORWARD TO SEEING YOU AT OUR SYMPOSIUM

FAP: THERAPY, IMAGING, AND BEYOND  
SATURDAY 23 MARCH, 10.45-11.45 AM



3B Pharmaceuticals



## Table of contents

Welcome Message .....	4
General Information A – Z .....	6
Invited Speakers .....	8
Scientific Committee .....	10
List of ePosters .....	11
Program Overview .....	16
PreCongress Program .....	18
Scientific Program   Friday, 22 <sup>nd</sup> of March .....	23
Scientific Program   Saturday, 23 <sup>rd</sup> of March .....	26
Scientific Program   Sunday, 24 <sup>th</sup> of March .....	31
List of Sponsors .....	34
Exhibitorplan & Floorplan .....	46
Imprint .....	50

## WELCOME MESSAGE



Horacio Amaral,  
Congress President

Vasko Kramer,  
Congress President

Richard Baum,  
Co-Congress  
President

Frank Rösch,  
Co-Congress  
President

As you participate in the congress, we encourage you to take full advantage of the networking opportunities and meet like-minded people.

Once again, we welcome you to TWC 2024 and hope you have a productive and memorable congress experience. Thank you for being a part of it.

*Yours sincerely,  
Horacio Amaral, Vasko Kramer, Richard Baum, Frank Rösch*

## Dear Participants,

Welcome to the 7<sup>th</sup> Theranostic World Congress (TWC) in Santiago, Chile!

On behalf of the Scientific Advisory Board and the Organizing Committee, we are pleased to have you here to discuss, share knowledge and promote collaboration in the field of theranostics and radiomolecular precision medicine.

The program offers a wide range of presentations covering various topics such as prostate cancer, neuroendocrine tumors, targeting the tumor microenvironment, new radioisotopes and their production, novel radio-chemistry and chelators, combination therapies, and patient access. We invite you to explore the diverse range of presentations, whether through ePosters or oral sessions, as we showcase the latest advancements and discoveries in the field.

In addition, we are hosting a one-day pre-conference event focused on theranostics in South America. This event provides an opportunity for professionals to engage with the practical aspects of theranostics, contributing to the ongoing dialogue and development within our community.



**Announcement of the 8<sup>th</sup> Theranostic World Congress**

The Congress will be held in December 2025 in Cape Town, South Africa. More information will soon be available on the website at [www.theranostics-world-congress.org](http://www.theranostics-world-congress.org)

**Attendance Certificate**

All participants will receive a general certificate of attendance, which will be available for download approximately two weeks after the congress. You will be notified by email as soon as the download is possible.

**Catering**

Catering during the congress is on a self-pay basis.

**Coat Rack**

Items of clothing as well as wardrobe items can be handed in at the cloakroom in the entrance area. This service is free of charge.

Opening Hours: all days | 7:30 – 19:00

Valuables can generally not be accepted or stored.

**Internet Access**

WiFi is available everywhere on the premises:

**Name: W\_Conference**

**Password: TWC2024**

**Lost And Found**

Lost items can be handed in and collected at the registration desk.

**Opening Hours****Registration Desk**

Thursday, March 21, 2024 | 8:00 – 10:00 and 16:00 – 18:00

Friday, March 22, 2024 | 7:00 – 17:00

Saturday, March 23, 2024 | 7:30 – 17:00

Sunday, March 24, 2024 | 7:30 – 17:00

**Photographer**

An official photographer will be commissioned by the organizer to produce extensive photographic material for a lively presentation of the congress events. The film and sound recordings can be used by the KUKM for PR and advertising purposes for the TWC. If you do not wish to be photographed, please inform the photographer on site. After the congress, a selection of the photos will be available for download in the protected area. The KUKM reserves the right to use selected photos for marketing purposes.

**Transportation**

We recommend using our transfer company or Uber for transportation.

You can reach our **transportation service** at the following number:  
+56 2 2426 2176

If you want to arrange your transportation ahead of time you can also write an email: [reservas.nt@gmail.com](mailto:reservas.nt@gmail.com)

To order an **Uber**, use the Uber app, which can be downloaded from all common app stores.

Let us know at the registration counter and we will be happy to help you.



## INVITED SPEAKERS

### A

**Abarca, Lorena** (MINSAL, Chile)  
**Avila Rodriguez, Miguel** (Autonomous University of Mexico, Mexico)

### B

**Babich, John** (Ratio Therapeutics, USA)  
**Bachmann, Michael** (FZ Dresden-Rossendorf, Germany)  
**Bal, Chandrasekhar** (AIIMS, New Delhi, India)  
**Ballal, Sanjana** (AIIMS, New Delhi, India)  
**Barbosa, Nataly** (CTIC, Colombia)  
**Baum, Richard P.** (Curanosticum, ICPO, Germany)  
**Bednarz, Bryan P.** (Univ. Wisconsin, USA)  
**Beyer, Thomas** (University Vienna, Austria)  
**Buchpiguel, Carlos** (Hospital Sirio Libanes, Brasil)

### C

**Chen, Shawn** (LNC, Singapore)  
**Cherry, Simon** (UC Davis, USA)  
**Constanzo, Julie** (INSERM, Montpellier, France)  
**Cutler, Cathy** (Brookhaven National Laboratory, USA)

### D

**Delpassand, Ebrahim** (RadioMedix / Excel Diagnostics, USA)

### E

**Eiber, Matthias** (Technische Universität München, Germany)  
**Etchebehere, Elba** (University of Campinas, Brasil)  
**Evans, Paul** (GEHC, USA)

### F

**Flamen, Patrick** (Hôpital Universitaire de Bruxelles, Belgium)

### G

**Gagnon, Katherine** (GE Healthcare, Schweden)  
**Geshani, Munir** (Mount Sinai, USA)  
**Gestin, Jean-Francois** (COST, NOAR, France)  
**Giesel, Frederik** (Heinrich Heine University Düsseldorf, Germany)  
**Goic, Carolina** (PUCCH, Chile)  
**Gourni, Eleni** (Inselspital Bern, Switzerland, Switzerland)  
**Greifenstein, Lukas** (Curanosticum, Germany)  
**Günter, Thomas** (UCSF Stanford, USA)

### H-J

**Herth, Matthias** (University of Copenhagen, Denmark)  
**Hicks, Rodney** (University of Melbourne and Monash University, Australia)  
**Hofman, Michael** (PeterMac, Australia)  
**Huerta, Luis** (Cchen, Chile)  
**Iagaru, Andrei** (Stanford, USA)  
**Jeong, Jae Min** (Seoul National University, South Korea)

### K

**Kjaer, Andreas** (University of Copenhagen, Denmark)  
**Korde, Aruna** (IAEA, Austria)  
**Kossatz, Susanne** (TU Munich, Germany)  
**Krause, Bernd** (University Hospital Rostock, Germany)  
**Kulkarni, Harshad** (BAMF, USA)

## INVITED SPEAKERS

**Kunikowska, Jolanta** (Nuclear Medicine Department, Medical University of Warsaw, Poland)

### L

**Lapi, Suzanne** (University of Alabama, USA)  
**Lewis, Jason** (MSKCC, USA)

### M

**Maharaj, Masha** (South Africa, South Africa)  
**Mailman, Josh** (Norcal, USA)  
**Martin, Marcel** (University Mainz, Germany)  
**Martin, Sergio** (ALMA Observatory, Chile)  
**Matushita, Christina** (SBMN, Brasil)  
**Mena Cortes, Danny** (Hospital Angeles Lomas, Mexico)  
**Mock, Jacqueline** (Philochem, Switzerland)  
**Mossesian, Sherly** (Sofie Bioscience, USA)

### N

**Nadel, Helen** (Stanford, USA)

### P

**Paganelli, Giovanni** (European Institute of Oncology, Italy)  
**Perfecto Oliva, Juan** (CENTIS, Cuba)  
**Pouget, Jean Pierre** (INSERM, Montpellier, France)  
**Prasad, Vikas** (Mallinkrodt Institute of Radiology, USA)

### R

**Radchenko, Valery** (Triumph, University of British Columbia, Canada)  
**Racioppi, Silvia** (Oncologic Institute Alex Fleming, Argentina)

**Rey, Ana** (Hospital de las Clinicas, Uruguay)

**Rösch, Frank** (Johannes Gutenberg University Mainz, Germany)

### S

**Sarduy, Eduardo Aluicio** (Wisconsin Cyclotron Lab, USA)  
**Sartor, Oliver** (Mayo Clinic, USA)  
**Sathekge, Mike** (University of Pretoria, South Africa)  
**Schultz, Michael** (Perspective Therapeutics, USA)  
**Scott, Andrew** (Olivia Newton John Cancer Research Institute, Australia)  
**Shi, Kuangyu** (University of Bern, Switzerland)  
**Simecek, Jakub** (Trimt, Germany)  
**Singh, Baljinder** (PGIMER, Chandigarh, India)  
**van der Veken, Pieter** (University of Antwerp, Belgium)

### W

**Watabe, Tadashi** (Osaka University, Japan)  
**Weber, Wolfgang** (TU Munich, Germany)  
**Werner, Rudolf** (Frankfurt University Hospital, Germany)  
**Wirtz, Ralph** (Stratifyer, Germany)

### Z

**Zan, Elcin** (Weil Cornell University, USA)  
**Zhang, Jingjing** (University of Singapore, Singapore)



**A**

**Alonso, Omar** (Centro Uruguayo de Imágenes Moleculares, Uruguay)  
**Avila Rodriguez, Miguel** (UNAM, Ciudad de Mexico, Mexico)

**B**

**Barboza, Marycel** (Nuclear Medicine, Hospital Albert Einstein, Sao Paulo, Brasil)  
**Bastianello, Maria** (Universidad de Buenos Aires, CEMIC, Argentina)  
**Buchpiguel, Carlos** (Department of Radiology, University of Sao Paulo; Hospital Sirio Libanes, Brasil)

**C**

**Casale, Guillermo** (Laboratorio Bacon, Buenos Aires, Argentina)

**E**

**Echtebehere, Elba** (Nuclear Medicine, University of Campinas, Brasil)

**F**

**Faccio, Fernando** (Departamento de Imágenes Sanatorio San Gerónimo, Argentina)  
**Fernandez, Rene** (Positronmed, Chile)

**G**

**Granador, Carlos** (Hospital Universitario San Ignaci, Colombia)

**H**

**Huapaya, Danfer** (Clinica Anglo Americana, Lima, Peru)

**L**

**Lopez, Rafael** (Sociedade Brasileira de Medicina Nuclear, Brasil)

**M**

**Matushita, Cristina** (Pontificia Universidad Catolica de Rio Grande do Sul, Brasil)

**O**

**Olarte Casas, Miguel Angel** (UNAM, Ciudad de Mexico, Mexico)

**P**

**Perfecto Oliva, Juan** (CENTIS, Cuba)

**R**

**Racioppi, Silvina** (Head of Nuclear Medicine Theranostics, IO Alex Fleming, Argentina)  
**Rey, Ana** (Hospital de las Clinicas, Uruguay)  
**Rodriguez, Jose Luis** (Clinica Las Condes, Chile)

**S**

**Savio, Eduardo** (Centro Uruguayo de Imágenes Moleculares, Uruguay)

**COMBINATION THERAPIES**

*Reduced renal uptake of various radio-pharmaceuticals under sodium para-aminohippurate (PAH) co-medication* | Marian Meckel (ITM Isotope Technologies Munch SE, Munich, Germany) **#41**

*Activation of photosensitizers by medically relevant radionuclides and their potential for combined therapies* | Antonia Denkova (Delft University of Technology, Delft, Netherlands) **#53**

*Pre-clinical evaluation of [225Ac] Ac-DOTA-SP for glioblastoma tumor* | Ivanna Hrynchak (ICNAS Pharma, Coimbra, Portugal) **#76**

*Preliminary assessment of co-administration of alfa and beta PSMA radiopharmaceuticals in a mouse xenograft model* | Eduardo Savio (Centro Uruguayo de Imagenología Molecular, Montevideo, Uruguay) **#84**

*Peptide Targeted Radioligand Therapy (PTRT) using 177Lu-, 225Ac- and 90Y-labeled 3BP-3940 in combination with chemo- and/or immunotherapy in FAP-expressing, therapy-refractory solid tumors: Preliminary results and long-term follow-up in 56 patients* | Aditi Mishra (Curanosticum Wiesbaden-Frankfurt, Wiesbaden, Germany) **#91**

**MEDICAL PHYSICS & INSTRUMENTATION**

*Optimizing radiotherapeutic management of recurrent esthesioneuroblastoma: A case report utilizing post-therapy dosimetry* | Nathaly Barbosa (Fundación CTIC, Bogota, Colombia) **#12**

*Assessment of metabolic tumor burden in primary staging of rectal cancers using FDG PET/CT* | Victor Heringer (UNICAMP, Campinas, Brazil) **#25**

*Artificial Intelligence To Evaluate Metabolic Tumor Burden In Primary Staging Of Rectal Cancer With 18F-FDG PET/CT* | Elba Etchebehere (University of Campinas (UNICAMP), Campinas, Brazil) **#43**

*131I thyroid cancer dosimetry: Our first experience in Angeles Lomas Hospital, Mexico* | Danny Mena Cortes (Hospital Angeles Lomas, Mexico) **#52**

*Quality control for 225Ac radiopharmaceuticals in one device* | Jeroen Plomp (Delft University of Technology, Delft, Netherlands) **#56**

*Evaluation of decreasing staff dose exposure after the introduction of an automatic radiopharmaceutical injector* | Mario Malinconico (Comecer S.p.A, Castel Bolognese, Italy) **#64**

*Precision medicine meets imaging: Total body PET/CT and PET/MRI in theranostics* | Harshad Kulkarni (Bad Berka, Germany) **#83**

## NEUROENDOCRINE TUMORS

**Targeted radiopharmaceutical therapy with n.c.a. [<sup>177</sup>Lu]Lu-edotreotide in GEP-NET patients: Dosimetry methodology in the COMPETE sub-studies** | Jarosław Ćwikła (Diagnostic and Therapy Center – Gammed, Warsaw, Poland) #21

**Phase Ib portion of the ACTION-1 phase Ib/3 trial of RYZ101 in gastroenteropancreatic neuroendocrine tumors (GEP-NET) progressing after 177Lu somatostatin analogue (SSA) therapy: safety and efficacy findings** | Lee Miller (Miller Medical Communications Ltd, Brindle, United Kingdom) #51

**Theranostic approaches in neuroendocrine tumors: Insights from the Uruguay-an experience** | Nicolas Niell (CUDIM, Montevideo, Uruguay) #82

## NOVEL TARGETS &amp; CHEMISTRY

**Mucin 13 (MUC13) as an imaging target for radioimmuno-PET: Towards development of a theranostic strategy for colorectal cancer treatment** | Ryan Coll (The University of Texas MD Anderson Cancer Center, Houston, United States) #20

**Biodistribution, molecular imaging and efficacy evaluation of a novel GPC3-targeted radiopharmaceutical therapy for hepatocellular carcinoma** | Gary Li (RayzeBio, Inc., San Diego, United States) #23

**Pretargeted Ac-225 radioimmunotherapy (PRIT) of HER2-expressing gastric cancer using a self-assembling and disassembling bispecific antibody (SADA)** | Sara Rinne (Weill Cornell Medicine, New York, United States) #59

**Polimeric micelles as a platform for the development of nano-theragnostics in oncology.** | Mariano Portillo (Universidad de Buenos Aires, Buenos Aires, Argentina) #68

**225Ac-radiopharmaceuticals: main parameters influencing labeling and quality control of PSMA-617 and FAPI-2286 2.14.0.0** | Javier Giglio (Centro Uruguayo de Imagenología Molecular, Montevideo, Uruguay) #77

**Antibody fragments for radiopharmaceutical therapy of solid tumors: Dosimetry studies using 177Lu radiolabeled minibodies** | Gareth Smith (ImaginAb, Inglewood, United States) #81

**Comparison of Lumi804 with DOTAGA as chelators for 161Tb-labeled LLP2A conjugates targeting melanoma** | Carolyn Anderson (University of Missouri, Columbia, United States) #90

**Re-Imaging a high relaxivity, Manganese-based multimodal radiotheranostic agent as a multi-kinase inhibitor (MKI)** | CuhaWijay Sathiyajith (Cardiff University, Cardiff, UK) #98



**Development and testing of polymer-encapsulated, amine-functionalized iron-based contrast materials in animal model** | Heydari, F. (Dept. Biophysics and Radiation Biology, Semmelweis University, Budapest, Hungary) #99

**Development, In Vitro Characterization & In Vivo Testing of multimodal Prussian Blue nanoparticles in an animal model** | Forgách, László (Dept. Biophysics and Radiation Biology, Semmelweis University, Budapest, Hungary) #100

**Improvement of cancer contrast in MRI using core/shell nanoparticles and 9.4T MRI system** | Barbara Blasiak (Institute of Nuclear Physics, Krakow, Poland) #102

## PROSTATE CANCER

**Targeted 225Ac therapy for prostate and other solid tumors** | Christopher Leamon (Fusion Pharmaceuticals, Boston, United States) #6

**Application of 68Ga-PSMA PET/CT in diagnosis and management of prostate cancer patients** | Habibollah Dadgar (Nuclear Medicine and Molecular imaging, Razavi hospital, Mashhad, Iran) #11

**177Lu-PSMA in metastatic castration-resistant prostate cancer: Final analysis of a Brazilian multicentric study** | Elba Etchebehere (University of Campinas (UNICAMP), Campinas, Brazil) #31

**Targeted PSMA theranostics with instant one-step self-assembled coordination polymer nanoalloy** | Mohamed Sallam (Griffith University, Nathan, Australia) #35

- Dual Time PSMA PET/CT with Diuretics and Contrast to Detect Prostate Cancer Pelvic Metastases: Is There a Benefit?** | Elba Etchebehere (University of Campinas (UNICAMP), Campinas, Brazil) #45
- Retrospective analysis of castration-resistant prostate cancer patients treated with 177Lu-PSMA-617 therapy: Uruguay-an experience 2.14.0.0** | Gerardo Gabriel dos Santos Loureiro (CUDIM Uruguayan Centre Of Molecular Imaging – HC Clinical Hospital Dr. Manuel Quintela, Montevideo, Uruguay) #46
- Gold nanoparticles loaded with PT(IV) prodrugs for prostate cancer theranostics** | Lurdes Gano (Centro de Ciências e Tecnologias Nucleares, Instituto Superior Técnico, Campus Tecnológico e Nuclear, Bobadela LRS, Portugal) #58
- Paving the way for future PSMA inhibitors: Insights from comparative pre-clinical evaluations of structure modifications** | Katarína Hajduová (Institute of Molecular and Translational Medicine, Palacky University Faculty of medicine and dentistry, Olomouc, Czech Republic) #69
- Novel albumin binding 225Ac-PSMA inhibitors: preclinical assessment of the long-term toxicity** | Barbora Neuzilova (Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry Palacky University Olomouc, Olomouc, Czech Republic) #70
- Incidental acute COVID-19 infection during radioligand therapy** | Aditi Mishra (Curanosticum Wiesbaden-Frankfurt, Wiesbaden, Germany) #71

- Optimization of PSMA labeling with carrier added Lutetium-177** | Victoria Trindade (CUDIM, Montevideo, Uruguay) #85
- PSMA PET volume metrics estimated with artificial intelligence-based segmentation as predictor to 177Lu-IPsMA radioligand in patients with metastatic castrate resistant prostate cancer** | Irma Soldevilla Gallardo (INCan, CDMX, Mexico) #95
- DNA damage response gene mutations can affect the responsiveness to PSMA-radioligand therapy in a metastatic prostate cancer cell line** | Sebastian Wolfshöfer (Charité Universitätsmedizin Berlin, Berlin, Germany) #96
- Study of the effect of formulation variations on the radiolabeling of the SPECT radiopharmaceutical [99mTc]EDDA/HYNIC-IPsMA with 99mTc obtained by n-gamma activation in a nuclear research reactor** | Jorge Romero (Comision Chilena de Energia Nuclear) #101

## RADIOISOTOPES

- Diagnostic role of F18-FDG PET/CT in patients with differentiated thyroid cancer with thyroglobulin elevated and negative radioiodine scan TENIS syndrome** | Muhammad Sufyan Hamid (GINUM Hospital Gujranwala Pakistan, Gujranwala, Pakistan) #3
- Accelerating production of non-carrier added Actinium-225 (n.c.a. Ac-225)** | Christine Pennekamp (Northstar Medical Radioisotopes, LLC, Beloit, United States) #65

- Japan Astatine Community: An organization supporting the medical application of accelerator-produced short-lived alpha emitter 211At** | Kohshin Washiyama (Fukushima Medical University, Fukushima, Japan) #87

## TUMOR MICROENVIRONMENT DIAGNOSTICS

- Preliminary comparison of 68Ga-FAPI-46 against 18F-FDG, 68Ga-DOTATATE and 68Ga-Pentixafor PET/CT/MR imaging in the assessment of various cancer types** | Habibollah Dadgar (Nuclear Medicine and Molecular imaging, Razavi hospital, Mashhad, Iran) #18
- Feasibility and initial experience of chemokine receptor-4 (CXCR4) expression using 68Ga-Pentixafor (Pars-Cixafor™) and O-2-18F-fluoroethyl-L-tyrosine (18F-FET) PET-MR image fusion in low- and high-grade gliomas** | Habibollah Dadgar (Nuclear Medicine and Molecular imaging, Razavi hospital, Mashhad, Iran) #33
- 68Ga-FAPI PET/CT in multifocal pseudomyogenic hemangioendothelioma – A case report** | Lilian Yuri Itaya Yamaga (Hospital Israelita Albert Einstein, São Paulo, Brazil) #54
- Initial clinical experience with 68Ga-FAPI PET/CT versus 18F-FDG PET/CT for staging/restaging in lung cancer and sarcoma** | Lilian Yuri Itaya Yamaga (Hospital Israelita Albert Einstein, São Paulo, Brazil) #61
- Comparison between 68Ga-FAP PET/CT and post-therapy 177Lu-FAP SPET/CT**

- in patients with pancreatic ductal adenocarcinoma (PDAC) undergoing peptide targeted radioligand therapy (PTRT) using 177Lu-, 225Ac- and 90Y-labeled 3BP-3940** | Aditi Mishra (Curanosticum Wiesbaden-Frankfurt, Wiesbaden, Germany) #94

## TUMOR MICROENVIRONMENT THERAPEUTICS

- Feasibility and therapeutic potential of the 68Ga/177Lu-DOTATATE theranostic pair in patients with metastatic medullary thyroid carcinoma** | Habibollah Dadgar (Nuclear Medicine and Molecular imaging, Razavi hospital, Mashhad, Iran) #22
- Survival outcomes of follicular cell-derived radioiodine-resistant thyroid cancer patients treated with [177Lu] Lu-DOTA-GA-FAPi dimers radionuclide therapy** | Sanjana Ballal (All India Institute of Medical Sciences, New Delhi, India) #75
- Differences between  $\alpha$ - and  $\beta$ -emitting targeted radiotherapy on the tumor microenvironment using single cell analysis in preclinical brain tumors.** | Sydney Jackson (University of Pittsburgh Department of Neurological Surgery, Pittsburgh, United States) #88
- CD11b alpha therapy targeting tumor microenvironment for treatment of glioblastoma** | Ambika Parmar (University of Pittsburgh School of Medicine, Pittsburgh, United States) #92

PreCONGRESS		TWC CONGRESS				
Thursday, 21 <sup>st</sup> of March		Friday, 22 <sup>nd</sup> of March				
		Saturday, 23 <sup>rd</sup> of March				
		Sunday, 24 <sup>th</sup> of March				
8:15				8:15		
8:30	Opening Remarks	Opening Ceremony	Medical Physics & Instrumentation Session	Current State of Isotope Production	8:30	
8:45	ICPO Academy	Opening Lecture		Theranostic Pairs	8:45	
9:00					9:00	
9:15		9:15				
9:30				9:30		
9:45				9:45		
10:00	Coffee	Coffee / Exhibition	Coffee / Exhibition	Coffee / Exhibition	10:00	
10:15					10:15	
10:30	LATAM Symposium on Radiochemistry	Patient Access Session – Panel Discussion of ICPO / Oncidium	Industry Session I – 3B Pharma	Industry Session IV – Siemens Healthineers	10:30	
10:45					10:45	
11:00					11:00	
11:15	LATAM Symposium on Medical Physics	Healthcare System Readiness for RLT – Panel Discussion		Industry Session V – Joint Symposium	11:15	
11:30						11:30
11:45					11:45	
12:00		Lunch Break / Exhibition	Industry Session II – Novartis		12:00	
12:15					12:15	
12:30	Lunch Break				12:30	
12:45					12:45	
13:00			Industry Session III – ITM	Industry Session VI – GE HealthCare	13:00	
13:15		Neuroendocrine Tumors & others	Novel Targets & Chemistry Session	Novel Indication, Concepts & Genetics	13:15	
13:30					13:30	
13:45					13:45	
14:00	LATAM Symposium on Nuclear Medicine				14:00	
14:15					14:15	
14:30					14:30	
14:45					14:45	
15:00	Symposium on Access, Regulation & Coverage in LATAM	Coffee / Exhibition	Coffee / Exhibition	Coffee / Exhibition	15:00	
15:15					15:15	
15:30			Prostate Cancer	TME Diagnostics	Combination Therapies	15:30
15:45					15:45	
16:00					16:00	
16:15					16:15	
16:30					16:30	
16:45			TME Therapeutics		16:45	
17:00		ProstTIC24 Recap		Closing Ceremony	17:00	
17:15					17:15	
17:30		Poster Session			17:30	
17:45					17:45	
18:00			TME – Panel Discussion		18:00	
18:15					18:15	
18:30					18:30	
18:45					18:45	
19:00					19:00	
19:15					19:15	
19:30	SPEAKERS WELCOME – ROOF TOP HOTEL W	Transport to Event			19:30	
19:45					19:45	
20:00			PRESIDENTS DINNER – VISTA SANTIAGO			20:00
20:15						20:15
20:30						20:30
20:45					20:45	
21:00					21:00	

**8:30 – 8:45 Opening Remarks**— *Welcome Address*

Horacio Amaral, Vasko Kramer (all TWC), Fernando Faccio (Alasbimn, Argentina), Christina Matushita (SBMN, Brasil)

**08:45 – 10:00 ICPO Academy**— *Introduction of the ICPO Academy for Theranostics*

Richard P. Baum Md (Curanosticum Wiesbaden, Germany and President of the ICPO Academy for Theranostics)  
Odile Jaume (CEO ICPO Foundation)

— *Radiomolecular Precision Oncology Pillar*

Elcin Zan (MD, Weil Cornell Medicine, New York, USA)

— *Medical Physics Pillar*

Thomas Beyer (Medical University of Vienna, Vienna, Austria)

— *Radio Chemistry Pillar*

Frank Rösch (Johannes Gutenberg University, Mainz, Germany)

— *Nursing and Patient Management Pillar*

Josh Mailman (International Patient Advocate, San José, USA)

**10:00 – 10:30 Coffee****10:30 – 11:30 LATAM Symposium on Radiochemistry**— *Current Situation of Radiopharmacy and Nuclear Medicine in LATAM*

Miguel Avila Rodriguez (Autonomus University of Mexico)

— *Radiopharmacy in the Latin American Region: Fostering Development via Uruguay's Educational Offer*

Ana Rey (Hospital De Las Clinicas)

— *CPRs on Theranostics – How IAEA Supports Local Initiatives in LATAM*

Aruna Korde (IAEA, Austria), Valery Radchenko (TRIUMF, Austria)

— *Isotope Production on Solid Targets*

Katherine Gagnon (GE Healthcare)

**11:30 – 12:30 LATAM Symposium on Medical Physics & Instrumentation**— *131I thyroid cancer dosimetry: our first experience in Angeles Lomas Hospital, Mexico*

Danny Mena Cortes (Hospital Angeles Lomas, Mexico)

— *Multi-Point vs. Single-Point Dosimetry: Impact on tumor- and organ absorbed doses*

Nataly Barbosa (CTIC, Colombia)

— *AI-assisted evaluation of metabolic tumor volume for staging of solid cancers*

TBD

— *Precision Medicine Meets Imaging: Total Body PET/CT and PET/MRI in Theranostics*

Harshad Kulkarni (BAMF, USA)

— *Pannel discussion*

Moderator: Thomas Beyer

**12:30 – 14:00 Lunch Break****14:00 – 15:00 LATAM Symposium on Nuclear Medicine**— *Teragnóstico del Cáncer Diferenciado de Tiroides. Experiencia Cubana: 77 Años, Desde Saúl Hertz Hasta Hoy*

Juan Perfecto Oliva (CENTIS, Cuba)

— *Lu-177 PRRT/PSMA in the setting of patients needing dialysis*

Munir Geshani (Mount Sinai, USA)

— *177Lu-PSMA in Metastatic Castration-Resistant Prostate Cancer: Final Analysis of a Brazilian Multicentric Study*

TBD

— *Theranostic Centers of Excellence & Harmonization of Clinical Trials*

Elcin Zan (Weil Cornell University)

**15:00 – 16:00** **LATAM Symposium on Patient Access, Regulation & Coverage**

- *Ley Nacional de Cancer – Chiles Strategy to Provide Access to Oncological Treatments*  
Carolina Goic (PUCCH, Chile)
- *Long-term vision and strategic orientation of Cchen with regard to Theranostics*  
Luis Huerta (Cchen, Chile)
- *Current Regulation of Radiopharmaceuticals in Chile*  
Lorena Abarca (MINSAL, Chile)
- *Current Regulation of Radiopharmaceuticals in Brazil*  
Christina Matushita (SBMN, Brazil)
- *Current Regulation of Radiopharmaceuticals in Argentina*  
TBD
- *Panel Discussion incl. Regulators, Ministry, Patient Organizations, Scientific Societies*  
Moderator: TBD

**19:30 – 0:00**  
**SPEAKERS WELCOME –**  
**ROOF TOP HOTEL W**

Connect with fellow attendees and speakers over drinks with a stunning view of the city skyline.

*Please note that this exclusive networking event requires separate booking.*





# Theranostics for personalized cancer care

Empowering precision oncology



Personalized care requires personalized solutions.

Our integrated value chain of precision oncology tools equips theranostics programs with state-of-the-art solutions at every step of the theranostics care pathway.

Discover how we can empower you with the tools you need to plan, implement, and expand your program to meet the demands of tomorrow.

 Visit us at Booth D10



## 8:30 – 10:00 Opening Ceremony

- 8:30 — *Welcome Address*  
Horacio Amaral, Vasko Kramer, Richard Baum, Frank Rösch (all TWC), Helen Nadel (SNMMI, USA), Aruna Korde (IAEA, Austria)
- 9:15 — *Opening Lecture – “Searching for our cosmic origins – A decade of molecular spectroscopy with ALMA”*  
Sergio Martin (ALMA Observatory, Chile)

## 10:30 – 11:15 Patient Access Session – Panel Discussion

Moderator: Dr. Cristiana Gameiro, Oncidium Foundation Advisor

- Radiotheranostics Global Access: Discussion with Patients and Experts**
- *Building hope: navigating through the challenges and barriers to treatment access*  
Supported by ICPO and Oncidium Foundation

## 11:15 – 12:00 Healthcare System Readiness for RLT – Panel Discussion

Moderator: Prof. Dr. Richard Baum, ICPO/Curanosticum

- A multi-stakeholder panel discussion around key barriers and about how to tackle the increasing number of patients eligible for RLT**
- *The potential of RLT in cancer care in the next 10 years: Call to action for Healthcare Systems Readiness*

## 13:30 – 15:00 Neuroendocrine Tumors & others

Chairs: Mariela Agolti (Nuclear Medicine Center Clinica Modelo, Argentina), Mike Sathekge (University of Pretoria, South Africa)

- *20 years’ experience with 177Lu DOTATATE: from “one fits all concept” to a personalized PPRT in neuroendocrine tumors*  
Giovanni Paganelli (European Institute of Oncology, Italy)
- *Pediatric Theranostics: A blueprint for the future*  
Helen Nadel (Stanford, USA)

- *Specific binding of SSTR2-targeting PRRT agonists and antagonists to human bone marrow stem cells provide insights into their distinct hematotoxicity profiles*  
Susanne Kossatz (TU Munich, Germany)
- *Latest updates in Targeted Alpha Therapy (TAT) using 212Pb-DOTAMTATE for the treatment of metastatic SSTR-expressing neuroendocrine tumors, in PRRT naïve and progressed patients*  
Ebrahim Delpassand (RadioMedix / Excel Diagnostics, USA)
- *SSTR2 antagonists for diagnosis and therapy of neuroendocrine tumors – from instant kit-type attempts to alpha therapy*  
Lukas Greifenstein (Curanosticum, Germany)
- *Developments towards the clinical translation of CCK-R2 ligands for imaging and therapy of various cancers*  
Thomas Günter (UCSF Stanford, USA)

**15:30 – 17:00 Prostate Cancer**

**Chairs:** Carlos Buchpiguel (University of Sao Paulo, Brasil), Elba Echtebehere (Universidade Estadual de Campinas, Brasil)

- *Prostate Cancer & PSMA-targeted Theranostics*  
Matthias Eiber (Technische Universität München, Germany)
- *Psmal Lu177: Randomized trials overview*  
Oliver Sartor (Mayo Clinic, USA)
- *New PSMA Theranostics*  
Jae Min Jeong (Seoul National University, South Korea)
- *225Ac-PSMA RLT of advanced prostate cancer*  
Mike Sathekge (University of Pretoria, South Africa)
- *225Ac-PSMA-617 Alpha Therapy: Current status in treating aggressive prostate cancer*  
Chandrasekhar Bal (AIIMS, New Delhi, India)

- *[177Lu]Lu-LF1: A Gastrin releasing peptide receptor radioantagonist with great promise in advancing prostate cancer treatment*  
Eleni Gourni (Inselspital Bern, Switzerland)
- *A Decade of GRPR PET Imaging – “Where are we and where are we going”?*  
Andrei Iagaru (Stanford, USA)

**17:00 – 17:30 ProsTIC24 Recap**

- *ProsTIC24 Recap*  
Michael Hofman (PeterMac, Australia)

**17:30 – 18:30 Poster Session**

► 19:00 – 20:00 TRANSPORT TO EVENT ◀

**19:30 – 0:00 SOCIAL EVENING – VISTA SANTIAGO**



Indulge in an evening of networking and camaraderie at VISTA SANTIAGO for our Social Evening event!

*Please note that this exclusive networking event requires separate booking.*



8:30 – 10:00

**Medical Physics & Instrumentation**

Chairs: Danny Mena Cortes (Hospital Ángeles Lomas, Mexico), Wolfgang Weber (TU Munich, Germany)

- *Whole-body PET/CT and what it can contribute to the development of new theranostic approaches*  
Simon Cherry (UC Davis, USA)
- *A framework to engage the imaging community in advancing total-body PET*  
Thomas Beyer (University Vienna, Austria)
- *Knowledge-guided artificial intelligence for personalized nuclear medicine theranostics*  
Kuanguyu Shi (University of Bern, Switzerland)
- *Alpha-Particle Dosimetry*  
Bryan Bednardz (Univ. Wisconsin, USA)
- *Transforming theranostics: integration of ai and machine learning for precision molecular imaging*  
Harshad Kulkarni (BAMF, USA)
- *Panel Discussion*  
Moderator: Thomas Beyer

10:45 – 11:45

**Industry Session I**

3b-Pharma  
FAP: Therapy, Imaging, and Beyond

- *Development of a novel FAP molecule for radioligand therapy*  
Dr. Lindsey Rolfe and Dr. Christiane Smerling, 3BP
- *SCINTIX biology-guided radiotherapy with RXM-5201*  
Dr. Thorsten Melcher, RefleXion Medical
- *SPECTROFAP – FAP imaging for SPECT*  
Dr. Jan Lennart von Hacht, 3BP

12:15 – 12:45

**Industry Session II**

Novartis  
*How Partnerships can support innovation & evolution of RLT in the future*

- *Introductions & setting the stage on RLT potential across solid tumors*  
Jeevan Virk, Therapeutic Area Strategy Head, RLT
  - *Fire-side chat with representatives*  
Michael Hofman; Chandrasekhar Bal; Mike Sathekge
1. RLT has the potential to become the essential future pillar of cancer care and numerous CTs are ongoing across various solid tumors; which are the barriers to enter and what are the potential solution to speed up development by using the unique properties of RLT?
  2. Clinical trials are often slow to start in this space due to the number of onsite approvals; how can we educate our respective stakeholders to get the RLT innovation to all eligible patients timely? Are there any other stakeholders that we need to involve?

13:00 – 13:30

**Industry Session III**

ITM Isotope Technologies Munich SE

- *Emitting Excellence: Illuminating the evolving landscape of Radiopharmaceutical Therapy*
- From 2004 to 2024, ITM has evolved from a company which has developed and commercialized no carrier added <sup>177</sup>Lu into a fully-fledged radiopharmaceutical company with a robust radiotherapeutic pipeline.
- Join us to discuss the journey from radioisotope production to the treatment of patients with neuroendocrine tumors and other oncology conditions and find out how these advancements are shaping therapeutic outcomes and paving the way for a brighter future in healthcare.

**13:30 – 15:00 Novel Targets & Chemistry**

**Chairs:** René Leyva Montaña (CENTIS, Cuba), Jan Rijn Zeevaart (Necsa, South Africa)

- *Recent progress of integrin-targeted theranostics*  
Jakub Simecek (Trimt, Germany)
- *Imaging of CXCR4 expression in patients with hematologic neoplasms*  
Andreas Buck Werner (University Hospital Würzburg, Germany)
- *Emerging 68Ga-Pentixafor PET/CT Applications for targeting CXCR4 receptors in human cancers – An Indian experience*  
Baljinder Singh (PGIMER, Chandigarh, India)
- *177Lu-LNC1011: Striking the balance of circulation half-life and tumor accumulation for prostate cancer therapy*  
Shawn Chen (LNC, Singapore)
- *211At-PSMA for alpha-RLT of prostate cancer*  
Matthias Herth (University of Copenhagen, Denmark)
- *Novel targets beyond FAPI: HSP70, Gal3*  
Wolfgang Weber (TU Munich, Germany)

**15:30 – 16:30 TME Diagnostics**

**Chairs:** Munir Ghesani (Mount Sinai Health System, USA), Andrew Scott (Department Of Molecular Imaging And Therapy, Austin Health, Australia)

- *History and biology of FAP: implications for clinical use of new generation FAP-ligands*  
Andrew Scott (Department Of Molecular Imaging And Therapy, Austin Health, Australia)
- *Druglike, 18F-labeled PET tracers targeting fibroblast activation protein (FAP)*  
Pieter van der Veken (University of Antwerp, Belgium)
- *Overview of today's clinical applications and perspectives*  
Frederik Giesel (Heinrich Heine University Düsseldorf, Germany)  
– Online –

- *FAPI – Advancements in diagnostics*  
Sheryl Mossesian & Paul Evans (Sofie Bioscience & GEHC, USA)
- *FAPI Diagnostics: clinical impact and future role of FAPI-PET*  
Tadashi Watabe (Osaka University, Japan)  
– Online –

**16:30 – 18:00 TME Therapeutics**

**Chairs:** Michael Kreißl (University Hospital Magdeburg, Germany), Elisabeth Eppard (University Hospital Magdeburg, Germany)

- *Clinical applications and perspectives of 3BP-3940*  
Richard P. Baum (Curanosticum; ICPO, Germany)
- *FAPI-Dimers-Chemistry and preclinical evaluation*  
Marcel Martin (University Mainz, Germany)
- *Assessing the long-term impact of FAP dimer therapy in cancer treatment*  
Sanjana Ballal (AIIMS, New Delhi, India)
- *Next generation 64Cu- and 225Ac-labelled radioligands for FAP-targeted therapy*  
John Babich (Ratio Therapeutics, USA)
- *Novel FAP-targeting small molecule radio-conjugates with high and prolonged tumour uptake*  
Jacqueline Mock (Philochem, Switzerland)  
– Online –
- *Radiotheranostics with Dual Targeting Probe 68Ga-/18F-/177Lu-FAPI-RGD in diverse solid tumors*  
Jingjing Zhang (University of Singapore, Singapore)

**18:00 – 18:20 TME – Panel Discussion**

**Moderator:** Frank Rosch

- *Panel Discussion about latest advancements in TME diagnostics, therapeutics, and ongoing developments*

An established global key player in the **radioisotope & radiopharmaceutical** field.



Find out more about us and our products.

[www.itm-radiopharma.com](http://www.itm-radiopharma.com)

Follow us:



8:15 – 9:15

**Current State of Isotope Production**

Chairs: Aruna Korde (IAEA, Austria), Antero Abrunhosa (ICNAS, University of Coimbra, Portugal)

- *Current status of DOE Isotope Production Program for theranostic radionuclides*  
Cathy Cutler (Brookhaven National Laboratory, USA)
- *Current status of Canadian Isotope Production Program for theranostic radionuclides*  
Valery Radchenko (Triumph, University of British Columbia, Canada)
- *At-211: Recent progress in isotope production, pharmaceutical chemistry, clinical translation*  
Jean-Francois Gestin (COST, NOAR, France)
- *Pb203 Image Guided Pb212 Alpha Particle Therapy for cancer – A global solution for multiple indications*  
Michael Schultz (Perspective Therapeutics, USA)

9:15 – 10:00

**Theranostic Pairs**

Chairs: Katherine Gagnon (GE Healthcare, Sweden), Miguel Avila Rodriguez (UNAM, Mexico)

- *Cu-64/67: Recent progress in isotope production, pharmaceutical chemistry, clinical translation*  
Jason Lewis (MSKCC, USA)
- *Pb-203/212 & Sc-44/47: Recent progress in isotope production, pharmaceutical chemistry, clinical translation*  
Suzanne Lapi (University of Alabama, USA)
- *Y-86/90 & Sc-44: Recent progress in isotope production, pharmaceutical chemistry, clinical translation*  
Eduardo Aluicio Sarduy (Wisconsin Cyclotron Lab, USA)

10:30 – 11:15

**Industry Session IV**

Siemens Healthineers

**11:45 – 12:30 Industry Session V**  
 Joint Symposium  
 211At industrials within the World Astatine Community (WAC)

- *Introduction of WAC*  
 Jean-Francois Gestin, Ethan Balkin, Kohshin Washiyama
- *Industrial presentations*  
 Sumitomo Heavy industries (Taki Kazuya), Toshiba (Yasuhiro Suzuki), Ionetix (David Eve), Nusano (Gregory Moffitt), Atley Solutions (Milton Lönnroth), Tetrakit (Andreas Jensen), Astathera (Michael Zalutsky), Alpha fusion (Sunao Fujioka)

**12:45 – 13:05 Industry Session VI**  
 GE Healthcare International LLC

- *Building the future in theranostics*  
 Dr. Carlos Buchpiguel, Head of Nuclear Medicine at Sirio Libanes Hospital, Brazil (First Omni Legend 32 user in LATAM)

**13:30 – 15:00 Novel Indication, Concepts & Genetics**  
 Chairs: Rene Francisco Fernandez Belmar (Positronmed, Chile), Michael Hofman (PeterMac, Australia)

- *What doesn't kill me makes me strong!*  
 Rodney Hicks (University of Melbourne and Monash University, Australia)
- *uPAR Theranostics: Targeting the Invasive Phenotype*  
 Andreas Kjaer (University of Copenhagen, Denmark)
- *Immunostimulatory effects of targeted radioligand therapy*  
 Jean Pierre Pouget (INSERM, Montpellier, France)
- *Radionuclide Targeted Treatment for Glioma: Substance-P and PSMA*  
 Jolanta Kunikowska (Nuclear Medicine Department, Medical University of Warsaw, Poland)

- *Paradigm shift in bladder cancer treatment: Theranostic incubator concept to treat chemotherapy resistant muscle-invasive bladder cancer*  
 Ralph Wirtz (Stratifyer, Germany)
- *BRCA germline positive vs somatic BRCA and the impact on prostate cancer*  
 Masha Maharaj (South Africa, South Africa)

**15:30 – 17:00 Combination Therapies**  
 Chairs: Francois Lamoureux (Canadian Association of Nuclear Medicine, Canada), Rodney Hicks (University of Melbourne and Monash University, Australia)

- *Theranostics 2.0: Embracing the power of PSMA combinations*  
 Michael Hofman (PeterMac, Australia)
- *Combining radioligand therapy and immune checkpoint inhibitors: preclinical rationale and ongoing clinical trials*  
 Patrick Flamen (Hôpital Universitaire de Bruxelles, Belgium)
- *Combinatorial Theranostic targeting of tumors and the tumor microenvironment*  
 Michael Bachmann (FZ Dresden-Rossendorf, Germany)
- *GRPr Theranostics in prostate cancer*  
 Bernd Krause (University Hospital Rostock, Germany)  
 - Online -
- *Nanoparticle Enhanced Radioligand Therapy (NERT)*  
 Julie Constanzo (INSERM, Montpellier, France)
- *Enhancing the efficacy of theranostics with DNA damage repair inhibitors*  
 Andrew Scott (Olivia Newton John Cancer Research Institute, Australia)

## Title Sponsor

**3B Pharmaceuticals GmbH**  
Magnusstraße 11  
14193 Berlin | Germany  
www.3b-pharma.com



3B Pharmaceuticals GmbH (3BP) develops targeted radiopharmaceutical drugs and diagnostics for oncology indications with a high unmet medical need. As a leader in peptide discovery and optimization, 3BP has built a technology platform extending from hit identification to early clinical development. The company was founded in 2008 by a team of renowned experts in peptide drug discovery and nuclear medicine from Berlin, Bern, and Basel.

**Booth D09**

## Double Platin Sponsor

**Siemens Healthineers**  
Hartmannstrasse 16  
91052 Erlangen | Germany  
www.siemens-healthineers.com



Personalizing cancer care demands the right tools to get patients the right treatment at the right time. Our integrated value chain of precision oncology tools equips theranostics programs with state-of-the-art solutions at every step of the theranostics care pathway. Visit us at Booth #D10 to learn more about how Siemens Healthineers is empowering precision oncology.

**Booth D10**

## Platin Sponsor

**ITM Isotope Technologies Munich SE**  
Lichtenbergstraße 1  
85748 Garching/Munich | Germany  
www.itm-radiopharma.com



ITM is dedicated to providing precise cancer radiotherapeutics and diagnostics to meet the needs of patients, clinicians and partners through excellence in development, production and global supply. ITM is advancing a broad pipeline to provide patients with more effective targeted treatment to improve clinical outcome and quality of life.

**Booth C09**

### Advanced Accelerator Applications INTERNATIONAL SA (Novartis)

Rue de la Tor de l'Île 4  
1204 Genvè | France  
www.adacap.com



Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people's lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 250 million people worldwide.  
<https://www.novartis.com>

**Booth C04**

## Gold Sponsor

**GE Healthcare International LLC.,  
Agencia en Chile**  
17th floor, Las Condes, Región Metropolitana  
Los Militares 4611 | Chile



**Booth C01**

## Silver Sponsor

**Trasis**  
Rue Gilles Magnée 90  
4430 Ans | Belgium  
www.trasis.com



At Trasis we are dedicated to helping the medical community access new radio-labelled therapeutic and diagnostic substances easily and faster. To this end, we design, manufacture, sell and support high performance synthesizers (AllinOne, AllinOne mini, AllinOne S and EasyOne), Quality Control instrument (QC1) dose preparation equipment (Unidose), their shielding and accessories. We also develop customized synthetic methods and instruments. As certified GMP part I and Part II, we can provide GMP Active Pharmaceutical Ingredients (API) and support our customers with their regulatory affairs. Our proven radiopharmaceutical expertise, coupled with our high-end instruments, allow us to provide fully integrated solutions for an effective tracer production and faster transition from drug development to marketing authorization.

**Booth A15**

### Perspective Therapeutics

3, Chemin du Cyclotron  
1348 Louvain la Neuve | Belgium  
perspectivetherapeutics.com



Perspective Therapeutics is a clinical stage precision medicine company with a broad pipeline, and two prioritized lead programs in clinic. We are developing a new class of image guided alpha-particle treatments, with an initial focus on neuroendocrine tumors (NETs) and metastatic melanoma, and a robust discovery platform advancing our pipeline into the clinic. Perspective's personalized theranostic approach captures information

about a patient's cancer which is used to guide precise radiation therapy, killing cancers from the inside out. Alpha-particles generate more energy and travel a shorter distance compared to beta-particles, making them more cytotoxic, while reducing their effects on healthy tissue.

### IBA SA

3, Chemin du Cyclotron  
1348 Louvain la Neuve | Belgium  
www.iba-radiopharmasolutions.com



Choose excellence for your radiopharma production – IBA is the world leader for the supply of PET & SPECT cyclotrons for radiopharmaceuticals production. Headquartered in Belgium, IBA installed and supports over 320 cyclotrons and more than 750 Synthera® synthesizers across the world. Based on almost 40 years of experience, IBA RadioPharma Solutions helps nuclear medicine department to design, build and operate PET center for the production of radiopharmaceuticals used for the detection and treatment of cancer and other critical diseases.

**Booth B01**

## Shared Silver Sponsor

**MIM Software Inc.**  
25800 Science Park Dr, Suite 180  
44122 Cleveland, OH | United States of America  
www.mimsoftware.com



MIM Software Inc. provides practical imaging solutions in the fields of radiation oncology, radiology, nuclear medicine, urology, neuroimaging, and cardiac imaging. Combined with MIM's quick and easy AI-powered total tumor burden calculation, MIM SurePlan MRT and LiverY90 provide timesaving tools for

## LIST OF SPONSORS

organ and tumor segmentation, registration, and post-treatment voxel-based dosimetry.

### Booth A14

#### Eckert & Ziegler

Strahlen- und Medizintechnik AG  
Robert-Rössle-Straße 10  
13125 Berlin | Germany  
www.ezag.com



Tecnonuclear is a prominent Argentine company in the field of Nuclear Medicine, With a history spanning over 30 years within the Argentine market. In 2022, Tecnonuclear became a part of the Eckert & Ziegler group. Founded in Berlin in 1992 by Dr. Andreas Eckert and Jürgen Ziegler, Eckert & Ziegler is one of the world's leading suppliers of isotopic technology for medical, scientific, and industrial applications.

### Booth A14

#### TerThera b.v.

Minervum 7070  
4817 ZK Breda | Netherlands  
www.terthera.com  
Sub-exhibitor NTP



TerThera is a radionuclide production focused company based in The Netherlands. The founders and the staff of TerThera have decades of experience in the nuclear medicine industry and are giving their full focus on the production of the innovative and novel radionuclide Terbium-161 (Tb-161). TerThera is building a global platform to meet the growing demand for radionuclides in cancer healthcare and provides the first commercial product of its kind. Produced at the highest radiochemical grade, and soon available as GMP product, this carrier-free lanthanide (NCA) holds promise for Radioligand Therapy. Early research

suggests Tb-161 can improve the anti-tumor capabilities, especially for (micro)metastasized cancers, due to the highest addition of Auger and conversion electrons when compared to other known radiolanthanides.

### Booth A18

#### Silver Sponsor Online

#### MONROL NUCLEAR PRODUCTS CO.

Çam Pınarı 3  
34805 İstanbul | Türkiye  
www.monrol.com



Monrol is one of the world's largest nuclear medicine companies leading innovation for the development and manufacturing of GMP grade radioisotopes and radiopharmaceuticals having headquarters in Istanbul. Monrol is distributing its world-class radiopharmaceutical products portfolio with excellence in global markets. Monrol is a CDMO, providing early development support to its customers as well as offering fully integrated services for today's nimble, lean, virtual companies effectively taking new product concepts into clinical trials and demonstrating proof of concept and going into first-in-human studies. Monrol is committed to transform and improve patient journey in cancer treatment with its radiopharmaceutical products portfolio distributing to more than 70 countries around the globe.

#### Bronze Sponsor

#### TrisKem International

3 rue des Champs Geons  
35170 Bruz | France  
www.triskem-international.com



TrisKem International develops, manufactures and commercializes selective resins for the separation and quality control of radionuclides

## LIST OF SPONSORS

such as nca Lu-177, nca Tb-161, Ga-67/8, Zr-89, Cu-61/4/7, alpha emitters (e.g. Ac-225, Pb-212,...), Ge-68, Ti-44/5, Sc-43/4/7 and many other radionuclides for medical purposes. TrisKem also provides selective chromatography paper (DGA Sheets, CU Sheets, more under development) for quality control of radionuclides and generator effluents (Ra-223, Ac-225, Pb-212, Ga-68, Cu-61/4/7,...). Our R&D team is constantly working on the development of new resins and methods to help you with your separation needs. Contact us at [contact@triskem.fr](mailto:contact@triskem.fr) for more information.

### Booth C08

#### iPHASE

Unit 5 / 899 Wellington Rd  
92121 San Diego | USA  
www.iphase.com.au



### Booth A03

#### ICPO Foundation

Banneggstraße 57  
88214 Ravensburg | Germany  
www.icpo.foundation



ICPO is a private Foundation active in scaling global patient access to Radiomolecular Precision Oncology thanks to shared knowledge, standards and education through the establishment of an international collaborative network of ICPO certified centers. The International Centers for Precision Oncology Foundation (ICPO) was established in 2019 under German law by leading international medical practitioners and life sciences entrepreneurs. Recognizing a

paradigm shift in cancer care from one size fits all to a personalized approach, the ICPO Foundation is helping to build momentum to scale global patient access to Radiomolecular Precision Oncology to support this shift.

The ICPO Foundation aims to develop an international network of physical diagnostic and therapeutic Centers for Precision Oncology organized in a social franchise model based on shared know-how, certified education as well as design and process standardization that enables best clinical practice globally. For this purpose, the ICPO Academy for Theranostics was launched 2023. Furthermore, it is the ICPO Foundation's objective to empower its Centers by embedding them in a highly inclusive Community that spearheads its model and lives up to the Precision Oncology promise, by making it available to all patients in need, irrespective of country or social status. Learn more about the ICPO Foundation at [www.icpo.foundation](http://www.icpo.foundation) and about the ICPO Academy for theranostics at [www.theranostics.academy](http://www.theranostics.academy)

### Booth C07

#### Tema Sinergie

Via Malpighi 120  
48018 Faenza (Ra) | Italy  
www.temasinergie.com



Tema Sinergie is one of the leading companies worldwide providing a complete range of products and services for all professionals and institutions working with ionizing radiation. From synthesis and dispensing hot cells, to dose drawing systems, radiopharmaceutical injectors, monitoring systems and much more, Tema Sinergie is the ideal partner for every application within Nuclear Medicine.

### Booth A16

## LIST OF SPONSORS

### ABX-CRO advanced pharmaceutical services

Forschungsgesellschaft mbH  
Schössergasse 19  
01067 Dresden | Germany  
www.abx-cro.com



ABX-CRO is an international CRO providing standard & specialised clinical and non-clinical studies, with emphasis on neuroscience, oncology and diagnostic imaging. With a unique translational medicine approach, we are happy to develop products from first non-clinical to late-stage multicentre human studies, or to support marketing authorisation. Our dedicated Molecular and Functional Imaging Core Lab provides comprehensive turn-key solutions covering all aspects of pre-clinical and clinical imaging and dosimetry. We provide solutions for radiolabelling, dosimetry, regulatory issues and the intricacies of functional imaging that are frequently seen as major obstacles in the conduct of oncology and imaging trials.

#### Booth A06

### Elysia SA

rue du Sart-Tilman 375  
4031, Angleur | Belgium  
www.elysia-raytest.com



#### Booth C10

### Isotopia Molecular Imaging

Alexander Yannai St 39  
Petah Tikva 4927735 | Israel  
www.isotopia.co.il



Isotopia is a leader in diagnostic and therapeutic radioactive solutions. We produce and supply Lutetium (177Lu), both no-carrier-added (NCA) and carrier-added (CA), particularly for metastatic prostate cancer and neuroendocrine tumors. With consistent and sustainable supply, we have expanded globally with cutting-edge production facilities, in North America and Europe. Isotopia is a well-established platform for managing the entire process from manufacturing through to delivery. Our dedicated professional teams provide round-the-clock customer services, regulatory guidance, and support. We are excited about our global expansion, PSMA radiolabelling kit, Lutetium (177Lu) European marketing authorization, and distribution reinforcing our commitment to advancing personalized cancer care through Theranostics.  
isotopia-global.com

#### Booth A05

### ITELPHARMA Divisone Radiofarmaci ITEL TELECOMUNICAZIONI

Via Antonio Labriola Z.I. snc  
70037 Ruvo di Puglia (BA) | Italy  
itelpharma.com



#### Booth A11

### RayzeBio, Inc.

5505 Morehouse Drive, Suite 300  
San Diego, California 92121 |  
United States of America  
www.rayzebio.com



#### Booth A01

### ROTOP Pharmaka GmbH

Bautzner Landstr. 400  
01328 Dresden | Germany  
www.rotop-pharmaka.de

## LIST OF SPONSORS



ROTOP has an extensive expertise in the field of product development and product application as well as commercial cGMP production including distribution. At our facility, we combine the complete know-how from pharmaceutical development including regulatory affairs, cGMP manufacturing of APIs and sterile drug products as well as an independent Q-unit with several Qualified Persons (QP) to release drug products. For more information about our products and CDMO services visit:  
www.rotop-pharmaka.com.

#### Booth A17

### RQS Alexander Ruffani

Kantstraße 15  
01809 Heidenau | Germany  
www.rqs-ar.com



RQS (Ruffani Quality Solutions) was founded in 2017 and has years of experience in radiochemistry, radiopharmacy and analytical instrumentation. A growing team of experienced and motivated professionals with expertise in synthesis development, radiochemistry, GMP-compliant production processes and chromatography instrumentation will help you find the best possible solution for your work application.

In 2020, RQS expanded to the USA and established Ruffani Quality Solutions, LLC. to provide timely and flexible local service. Our colleagues are specialized in the planning of production facilities as well as their construction, for this purpose they have been involved in several projects especially on the East Coast. The team of now 10 employees worldwide is

ready to support you with all your requests and is looking forward to get in contact with you.

#### Booth A04

### SOFIE Co.

21000 Atlantic Blvd, Suite 730  
20166 Virginia | USA  
sofie.com



SOFIE's vision is to improve patient outcomes by developing and delivering molecular diagnostics and therapeutics (Theranostics). With its robust radiopharmaceutical production and distribution network, mature contract manufacturing services, and now, high value Theranostic intellectual property, SOFIE is poised to deliver on the promise of nuclear medicine. For more information, please visit <https://sofie.com> or contact [info@sofie.com](mailto:info@sofie.com)

#### Booth B03

### Yantai Lannacheng Biotechnology Co. Ltd.

Room 101, Bulding 52,  
No. 500 Binhai East Road, Muping District  
2641000, Yantai | China  
www.dcb-group.com



Yantai Lannacheng Biotechnology Co., Ltd., (LNC) was founded in 2021. As a wholly owned subsidiary of Yantai Dongcheng Pharmaceutical Group (Dongcheng), LNC is dedicated to develop and commercialize first-in-class radioligand theranostics, and is committed to becoming a global leader in radiopharmaceutical innovation. LNC has established its comprehensive industry chain covering early development, radiolabeling, and clinical studies.

#### Booth A07

## LIST OF SPONSORS

### ABX advanced biochemical compounds

Heinrich-Glaeser-Straße 10-14  
01454 Radeberg | Germany  
abx.de

# ABX

advanced biochemical compounds GmbH

ABX advanced biochemical compounds is a global frontrunner in radiopharmaceuticals, with a focus on positron emission tomography (PET) tracers. We develop and produce compounds and components for any kind of radiotracer – from PET and SPECT precursors, PET reagent kits and cassettes, to complete radiopharmaceutical drug production in GMP environment.

#### Booth A08

### COMECER S.P.A.

Via Maestri del Lavoro 90  
48014 Castel Bolognese | Italy  
www.comecer.com



AN ILLIATS COMPANY

#### Booth C05

### BEST CYCLOTRON SYSTEMS

7643 Fulleton Road  
22153 Springfield, YA | USA  
www.bestcyclotron.com



TeamBest®, through Best Cyclotron Systems (BCS), offers radioisotopes and production capabilities for nuclear medicine and radiotherapy with its range of cyclotron systems. BCS's mission is to create technology to provide healthcare options for various needs around the world. Our staff assists from the planning stage, detailed design, facility

construction, daily production, maintenance and emergency repair through the Team-Best® network. We provide solutions for PET-CT and molecular imaging radiopharmaceuticals with the same excellent customized care as demonstrated in our 40+ year history of radiotherapy support.

#### Booth C03

### SHINE Technologies, LLC

2500 Crosspark Road  
53546, Janesville | USA  
www.shinefusion.com



SHINE Technologies has the largest n.c.a. lutetium-177 production facility in North America. We offer a secure, stable supply of isotopes, and plan to become the first vertically integrated supplier of Lu-177 in the world.

#### Booth A13

### LABORATORIOS BACON SAIC

URUGUAY 136  
B1603dfd Villa Martelli | Argentina  
bacon.com.ar



#### Booth A09

### Global Morpho Pharma

8, Rue de la Fionie  
44240 La Chapelle Sur Erdre | France  
www.morphopharma.com



Global Morpho Pharma is a turnkey technology and service provider for the production and

## LIST OF SPONSORS

distribution of medical radioisotopes. We are developing innovative equipment and building efficient supply chains to enable our partners worldwide to manufacture or source nca Lu-177 and other radioisotopes of interest. We are dedicated to improving the accessibility and supply security of medical radioisotopes for the benefit of patients by providing convenient solutions to the rapidly expanding nuclear medicine ecosystem.

#### Booth A10

### Brunker BioSpin

15 Fortune Drive  
01821 Billerica, MA | USA  
www.bruker.com

#### Booth C02

### benfovir AG

Graefenhaeuser Straße 26  
64293 Darmstadt | Germany  
benfovir.com



benfovir AG is a clinical stage company developing drugs for the treatment of viral diseases and cancers. benfovir's drug candidate inhibits sugar and lipid metabolism, thereby preventing the generation of the crucial building blocks for cell proliferation and DNA repair, leading to a sensitization of tumors towards radiotherapy.

#### Booth A02

### Clarity Pharmaceuticals Ltd

4 Cornwallis St, National Innovation Centre  
2015 Eveleigh NSW | Australia  
www.claritypharmaceuticals.com



Clarity is a clinical stage radiopharmaceutical company focused on the treatment of serious

disease. The Company is a leader in innovative radiopharmaceuticals, developing Targeted Copper Theranostics based on its SAR Technology Platform for the treatment of cancer in children and adults.

#### CMR

Cargo City South, Bldg. 6386  
60549 Frankfurt | Germany



#### Booth C06

### PanTera nv

Boeretang 201  
2400 Mol | Belgium  
pantera-life.com/about



PanTera, an IBA and SCK CEN joint-venture, aims to secure the large-scale production of actinium-225 (225Ac), one of the most promising alpha-emitting radioisotopes to fight cancers. By working towards this large-scale production, PanTera's ultimate goal is to improve the accessibility of future innovative cancer therapy based on 225Ac and theranostics in general. More information can be found at: [www.pantera-life.com](http://www.pantera-life.com)

#### Booth B02

### U.S DOE Isotope Program

1 Bethel Valley Road  
37830 Oak Ridge | USA  
www.isotopes.gov



The U.S. Department of Energy Isotope Program supports the production, as well as

the development of production techniques, of radioactive and stable isotopes that are in short supply. Isotopes are high-priority commodities of strategic importance for the Nation and are essential for energy, medical, and national security applications and for basic research. A goal of the program is to make critical isotopes more readily available to meet domestic needs.

The National Isotope Development Center (NIDC) is funded by the U.S. Department of Energy Isotope Program (DOE IP). It serves as an interface with the user community and manages the coordination of isotope production across the program facilities at Argonne, Brookhaven, Idaho, Los Alamos, Oak Ridge, and Pacific Northwest National Laboratories. These facilities produce stable and radioactive isotopes in short supply using reactors, accelerators, and other methods.

#### Booth B04

### Joint Projekt – Bronze Sponsorship with Symposium

#### TetraKit Technologies ApS

Ole Maaloesvej 3  
2830, Virum | Denmark  
tetrakit.com



Technologies develops a tetrazine-based click chemistry platform to radiolabel any type of targeting vector. We focus on radiohalogens, including astatine-211 and iodine-131, making it as easy to label with these as it is with radiometals. The TetraKit platform enables rapid and versatile, plug-n-play lead optimization and practical and attractive modular radiosynthesis. We have demonstrated the platform on PSMA, octreotate, FAPI, and others. We are developing a proprietary lead program based on FAPI dimers, which are highly promising and show extended tumor residence, thereby enabling effective FAP-targeted therapy. We look for plat-

form-based research collaborations, drug development partnerships, and investment.

#### Booth D07

#### Alpha Nuclide (Ningbo) Medical

Technology Co., Ltd Hangzhou Bay New Area,  
136 Yuhai East Road R & D Building 43,  
Phase 2, Digital Economy Industrial Park  
315000, Ningbo | China



Alpha Nuclide is a radiopharmaceutical company focusing on the supply of astatine-211, providing research and development services as well as manufacturing services of radiopharmaceuticals, and development of targeted alpha-particle therapy agents in China. Alpha Nuclide is located in Zhejiang Province just outside of Shanghai, and equipped with two 30 MeV cyclotrons one of which is dedicated to At-211 production. Together with a full R&D radiopharmaceutical lab and a cGMP facility, Alpha Nuclide aim to provide R&D and clinical support in China and international partners.

#### Booth D01

#### Ionetix Corporation

3130 Sovereign Drive  
48911, Lansing, Michigan | USA  
www.ionetix.com



IONETIX Alpha is a US-based cyclotron and technology company providing full-service, alpha-emitting radioisotope production and end-to-end radiopharmaceutical, development and manufacturing services. Utilizing a proprietary cyclotron technology platform, Ionetix Alpha has developed innovative cyclotron accelerator solutions for, high-yield production of alpha-emitting radioisotopes used in therapeutic, radiopharmaceuticals. This

includes high-purity Actinium-225 (Ac-225) and Astatine-211 (At-211), alpha-emitting radioisotopes. Production and distribution of GMP grade, supply of these radioisotopes will begin in the second half of 2024.

#### D Booth 04

#### Toshiba Energy Systems & Solutions Corporation

72-34, Horikawa-cho, Saiwai-ku  
212-8585, Kawasaki | Japan  
www.global.toshiba/ww/company/energy.html



Toshiba group has four business cores, energy, social infrastructure, electronic devices, and digital solutions. We are a leading supplier of integrated energy solutions. With our long experience and expertise in a wide range of nuclear power equipment and plants and advanced technologies which are based on R&D for fusion, accelerator and so on – we contribute to new solutions in the field of healthcare. We are promoting to realize the next-generation healthcare services with advanced IoT and AI technologies utilizing our knowledge and know-how we have accumulated in energy system development and manufacturing.

#### Booth D03

**Alpha Fusion Inc.**  
2-8-B303 Suita-shi Yamadaoka  
565-0871 Osaka | Japan

#### Booth D06

#### Sumitomo Heavy Industries, Ltd.

5-2, Soubiraki-cho, Niihama  
792-8588, Thime | Japan  
www.shi.co.jp/english/index.html



Since its establishment, Sumitomo Heavy Industries, Ltd. has contributed to the society by providing advanced technologies related to

industrial machinery and infrastructure equipment to customers in the world. In particular, we have accumulated over 50 years of experience in the manufacture of accelerators, which have been applied to scientific, industrial and medical fields and have earned a high reputation.

In the nuclear medicine, Sumitomo PET radio-tracer production system (incl. cyclotron, target, synthesizer, etc.) were delivered to more than 220 sites in the world and have been contributed for the development of clinical use and new technologies (such as Theranostics).

#### Booth D05

#### Atley Solutions

Läraregatan 3  
411 33, Göteborg | Sweden  
atley.com



Atley Solutions is the world-leader in commercial production equipment for radiopharmaceuticals based on the promising alpha-emitter astatine-211. Atley's first hardware product, the Atley C100, allows for automated purification of At-211 from cyclotron targets, as well as automated radiolabeling compatible with a wide range of targeting molecules and labeling methods. Atley also provides non-clinical radiopharmaceutical development services which include access to At-211

#### Booth D02

#### Nusano

28575 Livingston Avenue  
91355, Valencia, CA | USA  
nusano.com

#### Booth D08

## Collaborating and Supporting Societies

### The Oncidium foundation

Rue Emile Francqui 6, boîte 5, BE,  
1435 Mont-Saint-Guibert | Belgium  
www.oncidiumfoundation.org



### ICPO Foundation

Banneggstraße 57  
88214 Ravensburg | Germany  
www.icpo.foundation



### Sociedad Chilena de Urología

Att.: Sra. Macarena Cisternas  
Esmeralda 678  
8320053 Santiago, Chile  
www.schu.cl



### Sociedad Chilena de Oncología Médica

Att.: Sra. Yuba Stancic S., secretaria  
Bernarda Morín 488, piso 2  
Providencia, Santiago, Chile  
www.scom.cl/v2



### UroTeragLatam

World Trade Center, of  
Montecitos 38, Ciudad de Mexico, Mexico  
uroteraglatam.com



## Logo Sponsor with Link

### Abdera Therapeutics

535 Middelfield Road  
94025 Menlo Park | USA  
abderatx.com



### Navigo Proteins GmbH

Heinrich-Damerow-Straße 1  
06120 Halle/Saale | Deutschland  
www.navigo-proteins.com



### Positronpharma SA

Julio Prado 738  
7501068 Santiago, Chile  
www.positronpharma.com



## Bronze Sponsor Roll-Up

### BioNTech SE

An der Goldgrube 12  
55131 Mainz | Deutschland  
www.biontech.com



# Reimagining Nuclear Medicine

Transforming patients' lives by leading innovation

Novartis is reimagining medicine to improve and extend people's lives. We deliver high-value medicines that alleviate society's greatest disease burdens through **technology leadership in R&D** and novel access approaches. In our quest to find new medicines, we consistently rank among the world's top companies investing in research and development. About **108,000 people** of more than **140 nationalities** work together to bring Novartis products to nearly **800 million people** around the world.



**Rich  
Oncology  
Pipeline**

Targeting multiple  
tumor types



## Reimagining

Nuclear medicine by  
developing drugs for targeted  
radioligand therapy and  
precision radioligand imaging



 **NOVARTIS**





## Congress Presidents

Prof. Dr. Horacio Amaral Pineda, *Santiago, Chile*  
 Dr. Vasko Kramer, *Santiago, Chile*

## Co-Congress Presidents

Prof. Dr. Richard P. Baum, *Wiesbaden, Germany*  
 Prof. Dr. Frank Rösch, *Berlin, Germany*

## CONGRESS VENUE

**HOTEL W SANTIAGO**  
 Isidora Goyenechea 3000, Las Condes  
 Santiago, Chile

## Organizer

The Congress Presidents assigned Kongress- und Kulturmanagement GmbH with the organization of the congress.

# KUKM

Kongress- und Kulturmanagement GmbH  
 Rießnerstraße 12B  
 99427 Weimar, Germany

fon: +49 3643 2468-0  
 email: info@kukm.de  
 www.kukm.de

## Services on site

For all services on site, please contact our local partner in Santiago.



Av. Pdte. Kennedy 5488, office 303 Torre Sur,  
 Vitacura, Santiago

fon: +56 2 3251 4970  
 email: eventual@eventual-latam.com  
 eventual-latam.com

## Print


die superpixel  
 Leipzig, Germany  
 www.diesuperpixel.de

Copy Deadline: March 8, 2024

MI-6310.BM.JV | © Siemens Healthineers AG 02.2024 | Data courtesy of New York-Presbyterian Hospital/Weill Cornell Medical Center, New York, New York, USA.

# Expanding your theranostics program?

Give your patients the level of precision care they need and the personalized treatment they deserve with comprehensive PET/CT and SPECT/CT theranostic solutions from Siemens Healthineers.



Proven molecular imaging solutions across the entire continuum of theranostic care.



**High spatial resolution and the fastest time of flight<sup>1</sup>** in PET/CT for small lesion detection.

**Improve therapy planning and deliver highly targeted therapy** at the right dose and at the right time.



**Precise and reproducible SPECT/CT quantification** to within 5%<sup>2</sup> accuracy for low, medium, and high energy isotopes.

**Optimize therapy monitoring and individualize future therapy planning** based on your patient's unique needs and treatment response.

Learn more at [siemens-healthineers.com/mi](https://www.siemens-healthineers.com/mi)

<sup>1</sup> Based on competitive literature available at time of publication. Data on file.

<sup>2</sup> Accuracy of Bq/ml quantification measured per NEMA NU1-2018 using a uniform cylinder phantom. Calibration method: NIST-traceable source.



## 3B Pharmaceuticals

### Discovering the future of Nuclear Medicine

Target	Candidate	Research	IND	Lead	Pre-clin	Phase I	Phase II	Phase III	Sponsor / Licensee
Fibroblast Activation Protein (FAP)	FAP-2286	<sup>177</sup> Lu							NOVARTIS
		<sup>68</sup> Ga							
Fibroblast Activation Protein (FAP)	FO-004	<sup>177</sup> Lu							3B Pharmaceuticals
Fibroblast Activation Protein (FAP)	ROO-5201	<sup>68</sup> Ga							SCINTIX reflexion
Fibroblast Activation Protein (FAP)	3BP-4901 SPECT-FAP	<sup>90</sup> Y							3B Pharmaceuticals
Neurotensin Receptor (NTR)	FPI-2059 (FPI-01087) (3BP-227)	<sup>225</sup> Ac						<sup>177</sup> Lu	Fusion
		<sup>68</sup> Ga							
Gastric Inhibitory Polypeptide Receptor (GIP-R)	3BP-3775	<sup>177</sup> Lu							3B Pharmaceuticals
Carbonic Anhydrase IX (CAIX)	DP-4452	<sup>177</sup> Lu							Debiopharm
		<sup>68</sup> Ga							
Prostate-Specific Membrane Antigen (PSMA)	3BP	<sup>225</sup> Ac, <sup>177</sup> Lu							3B Pharmaceuticals
Delta-like Ligand-3 (DLL3)	3BP	<sup>177</sup> Lu							3B Pharmaceuticals
		<sup>68</sup> Ga							
Undisclosed	3BP	<sup>177</sup> Lu							3B Pharmaceuticals
β-Cadherin	3BP	<sup>177</sup> Lu							3B Pharmaceuticals
		<sup>68</sup> Ga							
Urokinase-Type Plasminogen Activator Receptor (uPAR)	3BP	<sup>177</sup> Lu							3B Pharmaceuticals
		<sup>68</sup> Ga							
Undisclosed	3BP	<sup>177</sup> Lu							3B Pharmaceuticals
Undisclosed	3BP	<sup>177</sup> Lu							3B Pharmaceuticals
Undisclosed	3BP	<sup>177</sup> Lu							3B Pharmaceuticals

■ THERAPEUTIC RADIODIAGNOSTIC

■ SPECT OR PET IMAGING AGENT